Exact Sciences Corporation delivered strong results in the quarter, with fourth quarter revenue increased by 17%, or 28%, excluding COVID testing, to $553 million. Screening revenue climbed by 45% to $404 million, including a 3-point rise from PreventionGenetics. The company delivered an all-around beat in the quarter as 10,000 new healthcare professionals ordered Cologuard, bringing the total to over 302,000. Cologuard’s expansion is aided by the strong sales and marketing team in cancer diagnostics. Besides that, Precision Oncology’s revenue fell 4% to $143 million, excluding the loss of the company’s prostate business and a $2 million forex headwind increase of 1%. The company further established a strategic collaboration with VieCure to increase access to precision oncology diagnostics for patients and community oncologists in the United States. We give Exact Sciences Corporation a ‘Hold’ rating with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!